Skip to main content

Encorafenib Side Effects

Medically reviewed by Drugs.com. Last updated on Nov 3, 2023.

Applies to encorafenib: oral capsule.

Serious side effects of Encorafenib

Along with its needed effects, encorafenib may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking encorafenib:

More common

Rare

Other side effects of Encorafenib

Some side effects of encorafenib may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to encorafenib: oral capsule.

Hematologic

Very common (10% or more): Anemia (36%), hemorrhage (19%), leukopenia (13%), lymphopenia (13%), neutropenia (13%)[Ref]

Hypersensitivity

Common (1% to 10%): Hypersensitivity[Ref]

Musculoskeletal

Very common (10% or more): Arthralgia (46%), myopathy (23%), pain in extremity (11%), myalgia, back pain[Ref]

Ocular

Common (1% to 10%): Uveitis (e.g., iritis, iridocyclitis), visual impairment[Ref]

Metabolic

Very common (10% or more): Increased alkaline phosphatase (35%), hyperglycemia (28%), hypermagnesemia (26%), hyponatremia (18%), decreased appetite[Ref]

Hepatic

Very common (10% or more): Increased gamma glutamyl transferase (45%), increased ALT (29%), increased AST (27%)[Ref]

Oncologic

Common (1% to 10%): New primary melanoma, cutaneous squamous cell carcinoma (cuSCC) including keratoacanthoma (KA), basal cell carcinoma[Ref]

Other

Very common (10% or more): Pyrexia (30%), fatigue, peripheral edema[Ref]

Nervous system

Very common (10% or more): Fatigue (46%), headache (22%), dizziness (15%), peripheral neuropathy (12%), intracranial hemorrhage in the setting of new or progressive brain metastases (sometimes fatal)

Common (1% to 10%): Facial paresis, dysgeusia[Ref]

Renal

Very common (10% or more): Creatinine increased (93%)

Common (1% to 10%): Renal failure[Ref]

Cardiovascular

Very common (10% or more): Hypertension (e.g., pulmonary embolism, deep vein thrombosis, embolism, thrombophlebitis, thrombophlebitis superficial, thrombosis)

Uncommon (0.1% to 1%): QTc interval prolongation[Ref]

Dermatologic

Very common (10% or more): Rash (53%), hyperkeratosis (49%), alopecia (38%), dry skin (26%), pruritus (21%), skin papilloma (e.g., keratoacanthoma, squamous cell carcinoma, lip squamous cell carcinoma, squamous cell carcinoma of skin), melanocytic nevus

Common (1% to 10%): Panniculitis, new primary melanoma, basal cell carcinoma, skin papilloma, dermatitis acneiform, skin exfoliation, photosensitivity, panniculitis[Ref]

Gastrointestinal

Very common (10% or more): Nausea (41%), vomiting (30%), abdominal pain (28%), constipation (22%), diarrhea

Common (1% to 10%): GI hemorrhage (including rectal hemorrhage), hematochezia, hemorrhoidal hemorrhage, pancreatitis, colitis

Uncommon (0.1% to 1%): Pancreatitis[Ref]

Psychiatric

Very common (10% or more): Insomnia[Ref]

Frequently asked questions

References

1. Product Information. Braftovi (encorafenib). Array BioPharma Inc. 2018.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.